523 results on '"Chotivanich, Kesinee"'
Search Results
2. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
3. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
4. Correction: Yuhana et al. Rickettsial infections are neglected causes of acute febrile illness in Teluk Intan, peninsular Malaysia
5. A randomised trial of malaria vaccine R21/Matrix-M™ with and without antimalarial drugs in Thai adults
6. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open-label, randomised, controlled, adaptive platform trial
7. Immunofluorescence study of cytoskeleton in endothelial cells induced with malaria sera
8. Diagnosis of murine typhus by serology in peninsular Malaysia: A case report where rickettsial illnesses, leptospirosis and dengue co-circulate
9. Identification and function of a novel human memory-like NK cell population expressing CD160 in melioidosis
10. Mass drug administrations with dihydroartemisinin-piperaquine and single low dose primaquine to eliminate Plasmodium falciparum have only a transient impact on Plasmodium vivax: Findings from randomised controlled trials
11. The prognostic and diagnostic value of intraleukocytic malaria pigment in patients with severe falciparum malaria
12. Molecular markers of dihydroartemisinin-piperaquine resistance in northwestern Thailand
13. Artemisinin resistance in the malaria parasite, Plasmodium falciparum, originates from its initial transcriptional response
14. The impact of targeted malaria elimination with mass drug administrations on falciparum malaria in Southeast Asia: A cluster randomised trial.
15. Triple therapy with artemether–lumefantrine plus amodiaquine versus artemether–lumefantrine alone for artemisinin-resistant, uncomplicated falciparum malaria: an open-label, randomised, multicentre trial
16. Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers
17. Author Response: Primaquine in glucose-6-phosphate dehydrogenase deficiency: an adaptive pharmacometric assessment of ascending dose regimens in healthy volunteers
18. Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV)
19. Temporal changes in SARS-CoV-2 clearance kinetics and the optimal design of antiviral pharmacodynamic studies: an individual patient data meta-analysis of a randomised, controlled, adaptive platform study (PLATCOV)
20. Reference spectrophotometric values for glucose-6-phosphate dehydrogenase activity in two-to six-month-old infants on the Thailand-Myanmar border
21. On-Chip Impedance Spectroscopy of Malaria-Infected Red Blood Cells.
22. Falciparum but not vivax malaria increases the risk of hypertensive disorders of pregnancy in women followed prospectively from the first trimester
23. Pharmacometric assessment of primaquine induced haemolysis in glucose-6-phosphate dehydrogenase deficiency
24. Intestinal injury and the gut microbiota in patients with Plasmodium falciparum malaria
25. Study on the dielectrophoretic characteristics of malaria‐infected red blood cells
26. Challenges of Plasmodium vivax and Plasmodium knowlesi co-infection
27. Antiviral efficacy of molnupiravir versus ritonavir-boosted nirmatrelvir in patients with early symptomatic COVID-19 (PLATCOV): an open-label, phase 2, randomised, controlled, adaptive trial
28. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study
29. Overexpression of plasmepsin II and plasmepsin III does not directly cause reduction in Plasmodium falciparum sensitivity to artesunate, chloroquine and piperaquine
30. Clinical antiviral efficacy of remdesivir in COVID-19: an open label, randomized, controlled adaptive platform trial (PLATCOV)
31. Activity of Ivermectin and Its Metabolites against Asexual Blood Stage Plasmodium falciparum and Its Interactions with Antimalarial Drugs
32. Clinical antiviral efficacy of favipiravir in early COVID-19 (PLATCOV): an open- label, randomised, controlled adaptive platform trial
33. Early Origin and Recent Expansion of Plasmodium falciparum
34. Vivax malaria in pregnancy and lactation: a long way to health equity
35. Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples
36. Author response: Pharmacometrics of high-dose ivermectin in early COVID-19 from an open label, randomized, controlled adaptive platform trial (PLATCOV)
37. Differential Effect of Extracellular Vesicles Derived from Plasmodium falciparum-Infected Red Blood Cells on Monocyte Polarization
38. Antimalarial Property of Compounds from Propolis Extract as New Antimalarial Agent Candidates: In Vitro and In Silico Analysis
39. Sequestration and Red Cell Deformability as Determinants of Hyperlactatemia in Falciparum Malaria
40. Pf7: an open dataset of Plasmodium falciparum genome variation in 20,000 worldwide samples
41. Disease Severity and Effective Parasite Multiplication Rate in Falciparum Malaria
42. The dynamic of asymptomatic Plasmodium falciparum infections following mass drug administrations with dihydroarteminisin–piperaquine plus a single low dose of primaquine in Savannakhet Province, Laos
43. Reference spectrophotometric values for glucose-6-phosphate dehydrogenase activity in two-to six-month-old infants on the Thailand-Myanmar border
44. Clinical antiviral efficacy of remdesivir and casirivimab/imdevimab against the SARS-CoV-2 Delta and Omicron variants
45. Artemisinin resistance and malaria elimination: Where are we now?
46. Population transcriptomics of human malaria parasites reveals the mechanism of artemisinin resistance
47. Molecular surveillance of dihydroartemisinin-piperaquine resistance in northwestern Thailand
48. Extracellular Vesicles Derived from Early and Late Stage Plasmodium falciparum-Infected Red Blood Cells Contain Invasion-Associated Proteins
49. Pharmacometric assessment of the in vivo antiviral activity of ivermectin in early symptomatic COVID-19
50. Randomized Controlled Trial of Levamisole Hydrochloride as Adjunctive Therapy in Severe Falciparum Malaria With High Parasitemia
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.